Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Subscriber Content

Simcere to Develop Cancer Drug from OSI Pharma in China

publication date: Oct 20, 2009

Simcere Pharmaceutical Group (先声药业) has acquired the China rights to a dual-mechanism cancer drug from OSI Pharmaceuticals. Simcere must first obtain regulatory approval for OSI-930, and then it will produce and market the drug in China. In the US, OSI-930 has completed a Phase I trial. Terms of the agreement were not disclosed. More details...

Stock Symbols: (NYSE: SCR) (NSDQ: OSIP)

Sorry this page is available to subscribers only.If you're not a subscriber why not subscribe today?